Human prothrombin complex - Octapharma

Drug Profile

Human prothrombin complex - Octapharma

Alternative Names: 4-Factor PCC - Octapharma; Ocplex; Octaplex; Pronativ

Latest Information Update: 19 Apr 2016

Price : $50

At a glance

  • Originator Octapharma
  • Class Biological factors; Blood coagulation factors; Proteins
  • Mechanism of Action Factor IX stimulants; Factor VII stimulants; Factor X stimulants; Protein C inhibitors; Prothrombin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Surgical blood loss
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Surgical blood loss
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Surgical blood loss

Most Recent Events

  • 14 Apr 2016 No recent reports on development identified - Preregistration for Surgical blood loss in USA (IV)
  • 14 Apr 2016 Octapharma plans a phase III trial for Surgical blood loss in USA (IV) (NCT02740335)
  • 11 Dec 2013 Human prothrombin complex licensed to Pfizer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top